Venmax Drugs And Pharmaceuticals Ltd
BSE: VENMAX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Venmax Drugs And Pharmaceuticals Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Venmax Drugs and Pharmaceuticals Limited is an India-based manufacturer specialising in active pharmaceutical ingredients (APIs) and drug intermediates. The company operates a manufacturing facility in Telangana, supplying essential chemical compounds to pharmaceutical formulators for finished dosages.
Business Model
The company generates revenue through the production and sale of bulk drugs and intermediates, serving both domestic and international generic pharmaceutical markets. Its business model prioritises process optimisation and quality control to maintain its position as a supplier to the broader healthcare sector.
Growth Outlook
Growth is expected to be driven by the company's focus on process efficiency and its ability to cater to the demand for essential raw materials within the generic pharmaceutical space.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and potential regulatory inspections at its manufacturing facility.
- Market Competition. As a small-cap entity, the company faces intense competition from larger pharmaceutical manufacturers with greater economies of scale.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Geopolitical and Trade Risks. Exposure to international markets introduces risks related to currency fluctuations and changes in global trade policies for pharmaceutical ingredients.
Start your research today
Unlock AI insights, financials, peers and live data on Venmax Drugs And Pharmaceuticals Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2 Cr
TTM · standalone
NET PROFIT
₹0.02 Cr
TTM · standalone
EPS
₹0.03
TTM · standalone
RETURN ON EQUITY
3.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
1.6%
TTM · standalone
P/E
556.7x
Q1 FY26 · standalone
EV/EBITDA
2205.0x
Q1 FY26 · standalone
EBITDA MARGIN
0.5%
TTM · standalone
NET PROFIT MARGIN
2.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Venmax Drugs And Pharmaceuticals LtdVENMAX | ₹19 Cr | 532.67 | 1856.00 | 1810.0% | 0.5% | 3.3% | 1.6% | -49.9% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q1 FY26
Financials
Venmax Drugs And Pharmaceuticals Ltd
BSE: VENMAX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Venmax Drugs And Pharmaceuticals Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Venmax Drugs and Pharmaceuticals Limited is an India-based manufacturer specialising in active pharmaceutical ingredients (APIs) and drug intermediates. The company operates a manufacturing facility in Telangana, supplying essential chemical compounds to pharmaceutical formulators for finished dosages.
Business Model
The company generates revenue through the production and sale of bulk drugs and intermediates, serving both domestic and international generic pharmaceutical markets. Its business model prioritises process optimisation and quality control to maintain its position as a supplier to the broader healthcare sector.
Growth Outlook
Growth is expected to be driven by the company's focus on process efficiency and its ability to cater to the demand for essential raw materials within the generic pharmaceutical space.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and potential regulatory inspections at its manufacturing facility.
- Market Competition. As a small-cap entity, the company faces intense competition from larger pharmaceutical manufacturers with greater economies of scale.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Geopolitical and Trade Risks. Exposure to international markets introduces risks related to currency fluctuations and changes in global trade policies for pharmaceutical ingredients.
Start your research today
Unlock AI insights, financials, peers and live data on Venmax Drugs And Pharmaceuticals Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2 Cr
TTM · standalone
NET PROFIT
₹0.02 Cr
TTM · standalone
EPS
₹0.03
TTM · standalone
RETURN ON EQUITY
3.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
1.6%
TTM · standalone
P/E
556.7x
Q1 FY26 · standalone
EV/EBITDA
2205.0x
Q1 FY26 · standalone
EBITDA MARGIN
0.5%
TTM · standalone
NET PROFIT MARGIN
2.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26